C21 Investments Reports Strong Revenue & EBITDA Growth Amidst Significant Tax Uncertainty and Internal Control Weakness

summarizeSummary

C21 Investments reported strong annual revenue and EBITDA growth, but disclosed a significant $13.36 million uncertain tax liability and a material weakness in internal financial controls, alongside ongoing federal cannabis regulatory changes.

check_boxKey Events · Earnings and Guidance · CXXIF

• Strong Financial Performance

  Reported an 8.3% increase in revenue to $32.6 million and a 13% rise in Adjusted EBITDA to $5.52 million for fiscal year 2026, driven by the acquisition of a third dispensary. Working capital improved from a $452,928 deficiency to a $1.92 million surplus.

• Significant Uncertain Tax Position

  Disclosed a $13.36 million 'uncertain tax position' related to its aggressive stance against IRC Section 280E, which management's legal opinion does not meet the 'more likely than not' recognition threshold, posing a material financial risk.

• Material Weakness in Internal Controls

  Management concluded that internal controls over financial reporting were not effective due to inadequate segregation of duties and insufficient personnel with technical accounting knowledge, with a remediation plan underway.

• DEA Rescheduling of Medical Cannabis

  The DEA rescheduled FDA-approved and state-licensed medical marijuana to Schedule III on April 28, 2026. Adult-use cannabis remains Schedule I, with new administrative hearings scheduled for June 29, 2026, creating regulatory uncertainty for the company's primary business.

auto_awesomeAnalysis · CXXIF · Life Sciences

C21 Investments Inc. reported an 8.3% increase in revenue to $32.6 million and a 13% rise in Adjusted EBITDA to $5.52 million for fiscal year 2026, driven by the acquisition of a third dispensary. Despite this operational strength and an improved working capital position, the company faces significant financial and governance challenges. A substantial 'uncertain tax position' of $13.36 million (approximately 22% of its market cap) related to its aggressive stance against IRC Section 280E poses a material risk, as management's position does not meet the 'more likely than not' recognition threshold. Furthermore, management identified a material weakness in internal controls over financial reporting due to inadequate segregation of duties and insufficient accounting expertise, which could impact financial reporting reliability. The recent DEA rescheduling of medical cannabis to Schedule III is a major industry development, but its full impact on C21's adult-use cannabis business, which remains Schedule I, is still being assessed.